Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis.

Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD, Straus S, Ezzat S, Goldstein DP.

Thyroid. 2009 May;19(5):451-7. doi: 10.1089/thy.2008.0392. Review.

PMID:
19281429
2.

Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy.

Iyer NG, Morris LG, Tuttle RM, Shaha AR, Ganly I.

Cancer. 2011 Oct 1;117(19):4439-46. doi: 10.1002/cncr.26070. Epub 2011 Mar 22.

3.

Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study.

Teng CJ, Hu YW, Chen SC, Yeh CM, Chiang HL, Chen TJ, Liu CJ.

J Natl Cancer Inst. 2015 Nov 3;108(2). pii: djv314. doi: 10.1093/jnci/djv314. Print 2016 Feb.

PMID:
26538627
4.

Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma.

Bhattacharyya N, Chien W.

Ann Otol Rhinol Laryngol. 2006 Aug;115(8):607-10.

PMID:
16944659
5.

Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis.

Subramanian S, Goldstein DP, Parlea L, Thabane L, Ezzat S, Ibrahim-Zada I, Straus S, Brierley JD, Tsang RW, Gafni A, Rotstein L, Sawka AM.

Thyroid. 2007 Dec;17(12):1277-88. Review.

PMID:
18020916
6.

Weighing shadows: can meta-analysis help define the risk-benefit ratio of RAI treatment for low-risk thyroid cancer patients?

Schneider AB, Viana MA, Ron E.

Thyroid. 2009 May;19(5):435-6. doi: 10.1089/thy.2009.0091. No abstract available.

PMID:
19415992
7.

Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer.

Marti JL, Jain KS, Morris LG.

Thyroid. 2015 Jun;25(6):681-7. doi: 10.1089/thy.2015.0067. Epub 2015 May 6.

PMID:
25851829
8.

Risk of second primary breast cancer after radioactive iodine treatment in thyroid cancer: a systematic review and meta-analysis.

Zhang Y, Liang J, Li H, Cong H, Lin Y.

Nucl Med Commun. 2016 Feb;37(2):110-5. doi: 10.1097/MNM.0000000000000419.

PMID:
26513055
9.

A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors.

Sawka AM, Lakra DC, Lea J, Alshehri B, Tsang RW, Brierley JD, Straus S, Thabane L, Gafni A, Ezzat S, George SR, Goldstein DP.

Clin Endocrinol (Oxf). 2008 Sep;69(3):479-90. doi: 10.1111/j.1365-2265.2008.03222.x. Epub 2008 Feb 13. Review.

PMID:
18284643
10.

Radiotherapy for primary thyroid cancer as a risk factor for second primary cancers.

Chuang SC, Hashibe M, Yu GP, Le AD, Cao W, Hurwitz EL, Rao JY, Neugut AI, Zhang ZF.

Cancer Lett. 2006 Jul 8;238(1):42-52. Epub 2005 Jul 21.

PMID:
16039041
11.

Increased cancer incidence after radioiodine treatment for hyperthyroidism.

Metso S, Auvinen A, Huhtala H, Salmi J, Oksala H, Jaatinen P.

Cancer. 2007 May 15;109(10):1972-9. Erratum in: Cancer. 2007 Oct 15;110(8):1875.

12.

Second primary malignancies in thyroid cancer patients.

Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, Dondon MG, Abbas MT, Langlois C, Schlumberger M.

Br J Cancer. 2003 Nov 3;89(9):1638-44.

13.

Childhood thyroid cancers and radioactive iodine therapy: necessity of precautious radiation health risk management.

Kumagai A, Reiners C, Drozd V, Yamashita S.

Endocr J. 2007 Dec;54(6):839-47. Epub 2007 Oct 15. Review.

14.

Radioactive Iodine Therapy Did Not Significantly Increase the Incidence and Recurrence of Subsequent Breast Cancer.

Ahn HY, Min HS, Yeo Y, Ma SH, Hwang Y, An JH, Choi HS, Keam B, Im SA, Park do J, Park IA, Noh DY, Youn YK, Chung JK, Cho BY, Park SK, Park YJ.

J Clin Endocrinol Metab. 2015 Sep;100(9):3486-93. doi: 10.1210/JC.2014-2896. Epub 2015 Jul 6.

PMID:
26147607
15.

A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivors.

Sawka AM, Lea J, Alshehri B, Straus S, Tsang RW, Brierley JD, Thabane L, Rotstein L, Gafni A, Ezzat S, Goldstein DP.

Clin Endocrinol (Oxf). 2008 Apr;68(4):610-7. Epub 2007 Oct 31.

PMID:
17973944
16.

The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131)I dose over 37 GBq.

Khang AR, Cho SW, Choi HS, Ahn HY, Yoo WS, Kim KW, Kang KW, Yi KH, Park do J, Lee DS, Chung JK, Cho BY, Park YJ.

Clin Endocrinol (Oxf). 2015 Jul;83(1):117-23. doi: 10.1111/cen.12581. Epub 2014 Oct 10.

PMID:
25115234
17.

Risk of second non-breast cancer after radiotherapy for breast cancer: a systematic review and meta-analysis of 762,468 patients.

Grantzau T, Overgaard J.

Radiother Oncol. 2015 Jan;114(1):56-65. doi: 10.1016/j.radonc.2014.10.004. Epub 2014 Nov 7. Review.

PMID:
25454172
18.

Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy.

Lang BH, Wong IO, Wong KP, Cowling BJ, Wan KY.

Surgery. 2012 Jun;151(6):844-50. doi: 10.1016/j.surg.2011.12.019. Epub 2012 Feb 15.

PMID:
22341041
19.

Complications of radioactive iodine treatment of thyroid carcinoma.

Lee SL.

J Natl Compr Canc Netw. 2010 Nov;8(11):1277-86; quiz 1287. Review.

PMID:
21081784
20.

Salivary gland malignancy and radioiodine therapy for thyroid cancer.

Klubo-Gwiezdzinska J, Van Nostrand D, Burman KD, Vasko V, Chia S, Deng T, Kulkarni K, Wartofsky L.

Thyroid. 2010 Jun;20(6):647-51. doi: 10.1089/thy.2009.0466.

PMID:
20470209
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk